妇科癌症生物标志物驱动疗法的合理选择：我们知道得越多，就越清楚自己未知的越多。
Rational selection of biomarker driven therapies for gynecologic cancers: The more we know, the more we know we don't know.
作者信息
Liu Joyce, Westin Shannon N
机构信息
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, United States.
Department of Gynecologic Oncology and Reproductive Medicine, University of Texas MD Anderson Cancer Center, Houston, TX, United States.
出版信息
Gynecol Oncol. 2016 Apr;141(1):65-71. doi: 10.1016/j.ygyno.2016.01.003.
Abstract
Precision medicine is a rapidly evolving area in the treatment of gynecologic malignancies. Advances in sequencing technology have resulted in an increasing wealth of data regarding the genomic characteristics of ovarian, endometrial, and cervical cancers. These vast new datasets of information have led to novel insights into potential vulnerabilities and therapeutic targets for these cancers. However, unraveling the complex molecular changes within cancer cells to determine how best to attack these targets and to identify effective biomarkers of response remains a significant challenge. In this article, we review the current status of biomarker-driven targeted therapy in gynecologic malignancies.
摘要
精准医学是妇科恶性肿瘤治疗中一个快速发展的领域。测序技术的进步使得关于卵巢癌、子宫内膜癌和宫颈癌基因组特征的数据日益丰富。这些庞大的新信息数据集为这些癌症的潜在脆弱性和治疗靶点带来了新的见解。然而，解析癌细胞内复杂的分子变化以确定如何最佳地攻击这些靶点并识别有效的反应生物标志物仍然是一项重大挑战。在本文中，我们综述了生物标志物驱动的靶向治疗在妇科恶性肿瘤中的现状。
相似文献
1
Rational selection of biomarker driven therapies for gynecologic cancers: The more we know, the more we know we don't know.妇科癌症生物标志物驱动疗法的合理选择：我们知道得越多，就越清楚自己未知的越多。
Gynecol Oncol. 2016 Apr;141(1):65-71. doi: 10.1016/j.ygyno.2016.01.003.
2
Integrating Precision Medicine into the Contemporary Management of Gynecologic Cancers.将精准医学融入妇科肿瘤的当代管理中。
Curr Oncol Rep. 2022 Jul;24(7):889-904. doi: 10.1007/s11912-021-01163-2. Epub 2022 Mar 26.
3
Genomic-Based Therapy of Gynecologic Malignancies.基于基因组学的妇科恶性肿瘤治疗
Acta Med Acad. 2019 Apr;48(1):84-89. doi: 10.5644/ama2006-124.245.
4
Genomic insights in gynecologic cancer.妇科癌症的基因组学见解
Curr Probl Cancer. 2017 Jan-Feb;41(1):8-36. doi: 10.1016/j.currproblcancer.2016.11.001. Epub 2016 Nov 11.
5
The NCI-MATCH trial and precision medicine in gynecologic cancers.NCI-MATCH 试验与妇科癌症的精准医学。
Gynecol Oncol. 2018 Mar;148(3):585-590. doi: 10.1016/j.ygyno.2018.01.008. Epub 2018 Feb 1.
6
Genomic and Molecular Abnormalities in Gynecologic Clear Cell Carcinoma.妇科透明细胞癌的基因组和分子异常。
Am J Clin Oncol. 2020 Feb;43(2):139-145. doi: 10.1097/COC.0000000000000641.
7
Personalized Medicine in Gynecologic Cancer: Fact or Fiction?妇科肿瘤的个体化医学：事实还是虚构？
Obstet Gynecol Clin North Am. 2019 Mar;46(1):155-163. doi: 10.1016/j.ogc.2018.09.010.
8
Updates in the Use of Targeted Therapies for Gynecologic Cancers.妇科癌症靶向治疗的新进展。
Am Soc Clin Oncol Educ Book. 2024 Jun;44(3):e438582. doi: 10.1200/EDBK_438582.
9
Major clinical research advances in gynecologic cancer in 2018.2018 年妇科癌症的主要临床研究进展。
J Gynecol Oncol. 2019 Mar;30(2):e18. doi: 10.3802/jgo.2019.30.e18.
10
Personalized Medicine in Gynecologic Cancer: Fact or Fiction?妇科癌症的个体化医学：事实还是虚构？
Surg Oncol Clin N Am. 2020 Jan;29(1):105-113. doi: 10.1016/j.soc.2019.08.008.
引用本文的文献
1
Challenges in Implementing Comprehensive Precision Medicine Screening for Ovarian Cancer.实施卵巢癌综合精准医学筛查面临的挑战。
Curr Oncol. 2024 Dec 18;31(12):8023-8038. doi: 10.3390/curroncol31120592.
2
Elucidating Novel Targets for Ovarian Cancer Antibody-Drug Conjugate Development: Integrating In Silico Prediction and Surface Plasmon Resonance to Identify Targets with Enhanced Antibody Internalization Capacity.阐明卵巢癌抗体药物偶联物开发的新靶点：整合计算机模拟预测和表面等离子体共振以鉴定具有增强抗体内化能力的靶点。
Antibodies (Basel). 2023 Oct 16;12(4):65. doi: 10.3390/antib12040065.
3
Real-World Data From a Molecular Tumor Board: Improved Outcomes in Breast and Gynecologic Cancers Patients With Precision Medicine.真实世界数据来自分子肿瘤委员会：精准医学改善了乳腺癌和妇科癌症患者的预后。
JCO Precis Oncol. 2022 Jan;6:e2000508. doi: 10.1200/PO.20.00508.
4
Cellular Mechanism of Gene Mutations and Potential Therapeutic Targets in Ovarian Cancer.卵巢癌基因突变的细胞机制及潜在治疗靶点
Cancer Manag Res. 2021 Apr 8;13:3081-3100. doi: 10.2147/CMAR.S292992. eCollection 2021.
5
Developing a Prognostic Gene Panel of Epithelial Ovarian Cancer Patients by a Machine Learning Model.通过机器学习模型构建上皮性卵巢癌患者的预后基因panel
Cancers (Basel). 2019 Feb 25;11(2):270. doi: 10.3390/cancers11020270.
6
The HIV-protease inhibitor saquinavir reduces proliferation, invasion and clonogenicity in cervical cancer cell lines.艾滋病毒蛋白酶抑制剂沙奎那韦可降低宫颈癌细胞系的增殖、侵袭和克隆形成能力。
Oncol Lett. 2016 Oct;12(4):2493-2500. doi: 10.3892/ol.2016.5008. Epub 2016 Aug 16.
本文引用的文献
1
A Biomarker-enriched, Randomized Phase II Trial of Adavosertib (AZD1775) Plus Paclitaxel and Carboplatin for Women with Platinum-sensitive -mutant Ovarian Cancer.贝伐珠单抗联合紫杉醇和卡铂治疗铂敏感复发性卵巢癌的 II 期随机临床试验
**解析**：英文文本的主语为“A Biomarker-enriched, Randomized Phase II Trial”，翻译为中文时为了使译文更符合中文表达习惯，调整了语序，译为“贝伐珠单抗联合紫杉醇和卡铂治疗铂敏感复发性卵巢癌的 II 期随机临床试验”。
Clin Cancer Res. 2020 Sep 15;26(18):4767-4776. doi: 10.1158/1078-0432.CCR-20-0219. Epub 2020 Jul 1.
2
Phase II, 2-stage, 2-arm, PIK3CA mutation stratified trial of MK-2206 in recurrent endometrial cancer.MK-2206 治疗复发性子宫内膜癌的 2 期、2 臂、PIK3CA 突变分层的 II 期临床试验。
Int J Cancer. 2020 Jul 15;147(2):413-422. doi: 10.1002/ijc.32783. Epub 2019 Dec 13.
3
Carboplatin-paclitaxel compared to Carboplatin-Paclitaxel-Bevacizumab in advanced or recurrent endometrial cancer: MITO END-2 - A randomized phase II trial.卡铂-紫杉醇与卡铂-紫杉醇-贝伐珠单抗治疗晚期或复发性子宫内膜癌的比较：MITO END-2 - 一项随机 II 期试验。
Gynecol Oncol. 2019 Dec;155(3):406-412. doi: 10.1016/j.ygyno.2019.10.013. Epub 2019 Oct 31.
4
Safety and Antitumor Activity of Anti-PD-1 Antibody, Nivolumab, in Patients With Platinum-Resistant Ovarian Cancer.抗 PD-1 抗体纳武利尤单抗治疗铂耐药卵巢癌患者的安全性和抗肿瘤活性。
J Clin Oncol. 2015 Dec 1;33(34):4015-22. doi: 10.1200/JCO.2015.62.3397. Epub 2015 Sep 8.
5
Association of Polymerase e-Mutated and Microsatellite-Instable Endometrial Cancers With Neoantigen Load, Number of Tumor-Infiltrating Lymphocytes, and Expression of PD-1 and PD-L1.聚合酶 e 突变和微卫星不稳定型子宫内膜癌与新抗原负荷、肿瘤浸润淋巴细胞数量以及 PD-1 和 PD-L1 表达的关联。
JAMA Oncol. 2015 Dec;1(9):1319-23. doi: 10.1001/jamaoncol.2015.2151.
6
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency.错配修复缺陷肿瘤中的程序性死亡受体-1阻断
N Engl J Med. 2015 Jun 25;372(26):2509-20. doi: 10.1056/NEJMoa1500596. Epub 2015 May 30.
7
A phase 2 study of cediranib in recurrent or persistent ovarian, peritoneal or fallopian tube cancer: a trial of the Princess Margaret, Chicago and California Phase II Consortia.西地尼布用于复发性或持续性卵巢、腹膜或输卵管癌的2期研究：玛格丽特公主医院、芝加哥和加利福尼亚II期联合研究组的一项试验
Gynecol Oncol. 2015 Jul;138(1):55-61. doi: 10.1016/j.ygyno.2015.04.009. Epub 2015 Apr 17.
8
Pembrolizumab for the treatment of non-small-cell lung cancer.帕博利珠单抗治疗非小细胞肺癌。
N Engl J Med. 2015 May 21;372(21):2018-28. doi: 10.1056/NEJMoa1501824. Epub 2015 Apr 19.
9
A phase II evaluation of selumetinib (AZD6244, ARRY-142886), a selective MEK-1/2 inhibitor in the treatment of recurrent or persistent endometrial cancer: an NRG Oncology/Gynecologic Oncology Group study.一项关于选择性MEK-1/2抑制剂司美替尼（AZD6244，ARRY-142886）治疗复发性或持续性子宫内膜癌的II期评估：一项NRG肿瘤学/妇科肿瘤学组研究。
Gynecol Oncol. 2015 Jul;138(1):30-5. doi: 10.1016/j.ygyno.2015.04.005. Epub 2015 Apr 14.
10
A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation - An NRG Oncology/Gynecologic Oncology Group study.强效、高选择性聚（ADP-核糖）聚合酶（PARP）抑制剂维利帕尼治疗携带种系BRCA1或BRCA2突变的持续性或复发性上皮性卵巢癌、输卵管癌或原发性腹膜癌的II期评估——一项NRG肿瘤学/妇科肿瘤学组研究
Gynecol Oncol. 2015 Jun;137(3):386-91. doi: 10.1016/j.ygyno.2015.03.042. Epub 2015 Mar 24.
Zotero 插件